Table 1.
Characteristics of PLWH and people without HIV infection with SARS-CoV-2 infection
| Characteristic | PLWH (n = 63) | Controls (n = 108) | p-value |
|---|---|---|---|
| Age (y)a | 49 (36–55) | 56 (42–65) | 0.006 |
| Male sex, n (%) | 55 (87) | 41 (38) | <0.001 |
| Charlson index >2, n (%) | 15 (24) | 33 (31) | 0.344 |
| COVID-19 pneumonia, n (%) | 10 (16) | 28 (26) | 0.127 |
| Severe COVID-19 pneumonia, n (%) | 4 (6.3) | 8 (7.4) | 0.794 |
| CD4 cell counts (cells/mL)a | 717 (535–875) | — | — |
| Nadir CD4 (cells/mL)a | 306 (148–425) | — | — |
| Undetectable HIV RNA, n (%) | 61 (97) | — | — |
| Antiretroviral therapy, n (%) | 63 (100) | — | — |
| Positive anti-SARS-CoV-2 total antibodies 6 mo after COVID-19, n (%) | 54 (86) | 106 (98) | 0.002 |
| Seroreversion, n (%) | 7 (11) | 1 (0.9) | 0.004 |
| No response, n (%) | 2 (3) | 1 (0.9) | 0.555 |
| Anti-spike IgG antibodies 6 mo after COVID-19 (BAU/mL)a | 42.7 (16.2–236.5) | 231 (63–312) | 0.004 |
COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; PLWH, people living with HIV; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Median (Q1–Q3).